Decreased circulating IL-10 was recently shown to associate with the severity of NAFLD (Paredes-Turrubiarte et al. 2016), and treatment with a PEGylated IL-10 was shown to decrease liver lipid content, possibly acting on Kupffer cells (Chan et al. 2016). The gene discussed is IL10; the disease is metabolic dysfunction-associated steatotic liver disease.